Global Anti TIGIT Antibody Clinical Trials and Companies Insight 2023 Report Highlights:
- Global Anti TIGIT Antibodies Market Dynamics
- Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
- Anti TIGIT Antibodies In Clinical Trials : > 45
- Overview On Partnerships and Collaborations In The Global Anti TIGIT Antibodies Market
- Global Anti TIGIT Antibodies Market Outlook
- Competitive Landscape
Download Report: https://www.kuickresearch.com/report-anti-tigit-antibody-antibodies
The advent of therapeutic antibodies targeting PD-1/PD-L1 and CTLA-4 is considered as monumental step in cancer immunotherapy. Although these inhibitors have shown encouraging clinical outcomes as monotherapies, several other alternate pathways exists which modulate the immune response, suggesting that combinational approaches will enhance the overall survival rates and enhance the efficacy of treatment. The introduction of genomic fingerprinting has enhanced the knowledge of cancer biology and has led to identification of other immunoreceptors which are present in tumor microenvironment and has expression on target cells.
TIGIT, or T-cell immunoreceptor with immunoglobulin and ITIM domain, is a promising new target for cancer immunotherapy and is upregulated by immune cells including activated T cells, natural killer cells and regulatory T cells. The novel receptor competes with immunoactivator receptor CD226 (DNAM-1) for their ligands including CD155 and CD112. In vitro studies of targeting of TIGIT with antagonistic anti-TIGIT monoclonal antibodies in combination with PD-1 targeting antibodies have demonstrated potential to restore T-cell function and therapeutic efficacy in mice models. The encouraging response of blocking TIGIT has gained momentum in the market which has led to development of several drugs in clinical pipeline.
The dual blockade of PD-1 and TIGIT represents one of the promising combinational immunotherapy for cancer. The combinational approach has synergistic effect which led to proliferation and function of antitumor CD8+ T-cells, resulting in memory T cells, tumor rejection, and enhanced overall survival rates. Studies have shown that dual blockade of PD-1 and TIGIT has shown superior efficacy in comparison with monotherapies. Currently, about 50 clinical trials are ongoing which are evaluating the role of novel TIGIT inhibitors in combination with PD-1/PD-L1 antibodies. More recently, researcher’s initiated clinical trial to evaluate triple combination of first-in-class anti-PVRIG antibody, COM701, in combination with nivolumab (Opdivo) and the anti-TIGIT antibody, BMS-986207 in solid tumors.
The optimistic results from clinical trials have surged the pharmaceutical sectors to actively invest in this sector. The major pharmaceutical companies are adopting strategic alliances to secure their place in market. For instance, in December 2021, Novartis has signed license agreement and collaborated with Beigene for Ociperlimab (BGB-A1217), which will expand the company’s research and development activities in immune-oncology. Ociperlimab is novel TIGIT inhibitor which is being evaluated in phase-III clinical trial for the management of lung cancer, and additional studies are also ongoing in wide range of cancers. The other key players in the market include Roche, Merck, Ono Pharmaceutical, Innovent Bio, Compugen, among others.
At present, the robust pipeline of TIGIT inhibitors is mainly crowded by therapeutic monoclonal antibodies. However, the advancement in the field of science and promising response of TIGIT inhibitors in combinational therapies has led to development of several bispecific antibodies. The novel bispecific constructs helps in reducing the overall cost of development and therapy; and also enhance the efficacy of treatment. Currently, a few bispecific antibodies including AGEN1777, IBI321 and HLX301 have entered initial stages of clinical trials. Apart from cancer, researchers are also expanding the knowledge of TIGIT inhibitors in other therapeutic indications including HIV and autoimmune disorders, which are mainly confined to preclinical stages.